Skip to content
    Clinical Trials

    Atezolizumab Plus Neoadjuvant Chemotherapy in Early-Stage TNBC: Phase 3 NSABP B-59/GeparDouze Trial

    Loibl et alNature medicine

    Atezolizumab Plus Neoadjuvant Chemotherapy in Early-Stage TNBC: Phase 3 NSABP B-59/GeparDouze Trial
    The randomized, double-blind phase 3 NSABP B-59/GeparDouze trial evaluated the addition of atezolizumab (773 patients) or placebo (777 patients) to sequential taxane-carboplatin-anthracycline-based neoadjuvant chemotherapy in patients with stage II-III triple-negative breast cancer (TNBC).
    The study did not reach statistical significance for its primary endpoint of event-free survival (EFS), demonstrating a hazard ratio of 0.80 (95% CI, 0.062-1.03; stratified log-rank P = 0.083) and a 4-year EFS rate difference of 3.3%. Overall survival (OS) similarly showed no statistically significant improvement, with a hazard ratio of 0.86 (95% CI, 0.62-1.19) and a 4-year OS benefit of 0.7%.
    Safety analyses indicated grade ≥3 treatment-emergent adverse events occurred in 75.3% of patients receiving atezolizumab compared to 73.4% receiving placebo. Immune-related adverse events were more frequent in the atezolizumab arm (27.6% vs. 11.4%). Neoadjuvant treatment discontinuation occurred in 25.5% (196 patients) of the atezolizumab group versus 18.8% (143 patients) of the placebo group.
    Prespecified subgroup evaluations indicated potential benefit of atezolizumab among patients presenting with clinical lymph node involvement (P interaction = 0.039). Exploratory mRNA-based subset analyses suggested potential benefit in basal-like immune-activated tumors, indicating that TNBC subtyping and tumor-infiltrating lymphocyte (TIL) quantification may assist in identifying patient populations responsive to neoadjuvant immune checkpoint inhibition.

    Key Takeaways

    • In stage II-III TNBC, adding atezolizumab to neoadjuvant chemotherapy did not statistically significantly improve event-free survival (HR, 0.80; 95% CI, 0.062-1.03; P = 0.083; 4-year EFS difference, 3.3%) or overall survival (HR, 0.86; 95% CI, 0.62-1.19; 4-year benefit, 0.7%).
    • Atezolizumab increased immune-related adverse events (27.6% vs 11.4%) and neoadjuvant phase treatment discontinuation rates (25.5% vs 18.8%) compared with placebo, with grade ≥3 treatment-emergent adverse events occurring in 75.3% vs 73.4% of patients.
    • Prespecified subgroup analysis revealed significant EFS treatment-effect heterogeneity, demonstrating benefit with atezolizumab in patients presenting with clinical lymph node involvement (P interaction = 0.039).